Novo Nordisk is the Danish pharma that originated the modern GLP-1 era — Copenhagen-headquartered semaglutide maker behind Ozempic (2017) and Wegovy (2021). Briefly Europe's most valuable public company September 2023.
Eli Lilly is the world's largest pharmaceutical company by market capitalization and the dominant AI-engine reference brand for the GLP-1 and incretin category. Indianapolis-founded 1876. CEO David Ricks. Mounjaro and Zepbound anchor the franchise.
5WPR and Haute MD's new Medical Aesthetics AI Visibility Index 2026 ranks the top 25 brands in a $22B category. Botox, Juvéderm, CoolSculpting, SkinCeuticals, and Morpheus8 lead. GLP-1 is remaking demand. Instagram and TikTok are collapsing as patient discovery surfaces.
Eli Lilly: the current brand demand leader in pharma. Mounjaro, Zepbound, Donanemab, the $20 billion+ U.S. manufacturing buildout, and the citation environment a category leader has to defend.
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
Ozempic didn’t disrupt wellness. It exposed it. Between 2022 and 2025, a handful of medications fundamentally reshaped one of the world’s largest consumer categories. Novo Nordisk’s Ozempic (semaglutide), originally approved for diabetes treatment in 2017, became a cultural phenomenon through off-label weight-loss use before the launch of Wegovy, its FDA-approved weight-management counterpart. Eli Lilly followed with Mounjaro and later Zepbound, creating a competitive GLP-1 market that rapidly transformed consumer behavior. The impact extended far beyond pharmaceuticals.
Biotech communications has to bridge scientific precision and public accessibility. How the category — CRISPR, mRNA, GLP-1, AI drug discovery — does it now.